Finotonlimab plus Stapokibart for advanced head and neck cancer
Part of Cancer clinical trials.
This trial tests two drugs, Finotonlimab and Stapokibart, for people with head and neck cancer that has come back or spread to other parts of the body. It may help if you've already tried a PD-1 drug and platinum chemotherapy, but the cancer got worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer (in mouth, throat, or voice box) that has returned or spread.
- You have tried a PD-1 drug with or without platinum chemo, and your cancer got worse within 24 weeks after the last dose.
- You are at least 18 years old and your daily activity level is mild (ECOG 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your blood and organ function tests must meet certain safe levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SKB571 for people whose head and neck cancer (a type called squamous cell carcinoma) has come back or spread and cannot be surgically removed. The goal is to see if the drug is safe and effective.
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests giving a drug called finotonlimab (an immunotherapy that helps your immune system fight cancer) together with chemotherapy before and after surgery for stage II head and neck cancer. The goal is to see if this combination can improve outcomes for patients, and you will receive the treatment as part of your standard surgical care.
This trial tests a new drug called stapokibart combined with another immunotherapy to see if it can help people with lymphoma that has come back or not responded to earlier treatments. The goal is to shrink tumors or slow the cancer's growth.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.